Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | TP53 | P04637 | 7/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091022 | 0.80 | TP53 (0.89) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091113 | 0.79 | MAPT (0.75) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL13091084 | 0.78 | MAPT (1.00) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091087 | 0.78 | TP53 (1.00) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL13091118 | 0.77 | TP53 (0.78) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091089 | 0.77 | MAPT (1.00) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091108 | 0.77 | MAPT (0.72) | MAPTTP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL13091085 | 0.77 | TP53 (1.00) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091034 | 0.77 | TP53 (1.00) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091104 | 0.76 | MAPT (0.90) | MAPTTP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2009023558-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | BAX, BCL2, BAD | MAPT 2663/4885TP53 34/4885POLB 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.